Luke Higgins, MD (he/him)

How do state-wide quality measures impact #radonc fractionation selection for 🦴 metastases? Within the Michigan Radiation Oncology Quality Consortium, quality measures were implemented in 2020 and 2022 to promote use of single fx (SFRT) and <=5 fx treatments for pts w/ 🦴 mets. From 2018-2024, 3247 pts in 29 centers were treated w/ 4382 (non-SBRT)☢️ plans: 🔘Use of SFRT 🔼 from 17.8% ➡️ 38.8% 🔘Use of <=5 fx tx 🔼 from 44.2% ➡️ 63.9% 🔘Use of shorter regimens was assoc w/ later yr of tx, 🔼 distance to tx facility, 🔼 baseline fatigue, 🔽 yr of physician practice 🔗 - tinyurl.com/ypw2tzbn @ASTRO_org @LukeMHiggins @UMichRadOnc

⁦@ASTRO_org⁩ Annual Meeting is just around the corner. I wanted to bring your attention to a session on Sunday Michigan Radiation Oncology Quality Consortium (MROQC) is a unique collaboration between an insurance payer, LAMC and community programs across Michigan. 1/2

Interesting to see a paper concerning omission of adjuvant ET in @JCO on early-stage breast cancer that doesn’t account for radiotherapy as a potential confounder. Could it be that patients were did not receive adjuvant ET also tended to decline radiotherapy as well? #radonc